Invesco Ltd. Has $4.11 Million Stock Position in Adaptive Biotechnologies Corporation $ADPT

Invesco Ltd. grew its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 218.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 552,531 shares of the company’s stock after purchasing an additional 378,940 shares during the quarter. Invesco Ltd. owned about 0.36% of Adaptive Biotechnologies worth $4,105,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Soleus Capital Management L.P. increased its position in Adaptive Biotechnologies by 168.1% during the fourth quarter. Soleus Capital Management L.P. now owns 2,983,142 shares of the company’s stock worth $17,884,000 after buying an additional 1,870,393 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Adaptive Biotechnologies by 9,892.2% during the 1st quarter. Victory Capital Management Inc. now owns 1,764,227 shares of the company’s stock worth $13,108,000 after acquiring an additional 1,746,571 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Adaptive Biotechnologies by 794.0% during the 4th quarter. Ameriprise Financial Inc. now owns 736,720 shares of the company’s stock valued at $4,417,000 after acquiring an additional 654,309 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Adaptive Biotechnologies by 397.6% in the 4th quarter. Deutsche Bank AG now owns 630,577 shares of the company’s stock valued at $3,783,000 after acquiring an additional 503,842 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Adaptive Biotechnologies by 89.2% in the 4th quarter. Point72 Asset Management L.P. now owns 937,331 shares of the company’s stock valued at $5,619,000 after acquiring an additional 441,839 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Trading Up 2.6%

Shares of ADPT stock opened at $13.31 on Friday. The firm has a market capitalization of $2.03 billion, a P/E ratio of -16.23 and a beta of 1.92. Adaptive Biotechnologies Corporation has a 1 year low of $3.98 and a 1 year high of $13.52. The firm’s fifty day simple moving average is $11.63 and its 200 day simple moving average is $9.56.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. The firm had revenue of $49.94 million during the quarter, compared to the consensus estimate of $49.40 million. During the same period in the prior year, the firm earned ($0.31) EPS. The business’s revenue was up 36.3% on a year-over-year basis. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ADPT shares. Morgan Stanley upped their target price on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Monday, May 5th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Piper Sandler raised their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Craig Hallum assumed coverage on shares of Adaptive Biotechnologies in a report on Wednesday, June 18th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.38.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.